Ozempic Gastroparesis Settlement: New York Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Safety Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy has empowered individuals to make informed decisions about their well-being, often by distilling complex clinical data into accessible knowledge. Within this tradition, the focus has naturally expanded to include emerging pharmaceutical therapies and their broader implications for patient safety. As the landscape of chronic disease management evolves, so too does the need to examine the real-world consequences of widely prescribed medications. One such area of growing attention involves glucagon-like peptide-1 receptor agonists, originally developed for metabolic regulation. While these agents have demonstrated efficacy in their intended indications, post-market surveillance and patient reports have raised questions about potential gastrointestinal adverse effects, particularly in individuals with prolonged exposure. This pivot from general health education to a more targeted concern reflects a natural progression: from understanding a drug's mechanism in principle to scrutinizing its risk profile in practice. For those who have experienced significant gastrointestinal complications following use of these therapies, the conversation shifts from clinical overview to personal impact. In this context, legal considerations emerge, particularly for individuals in New York seeking representation for alleged injuries such as gastroparesis. The transition from broad health literacy to specific occupational or therapeutic exposure concerns underscores the importance of vigilance in pharmaceutical safety monitoring.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Clinical trial data show that gastrointestinal adverse reactions occur significantly more often with Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea episodes occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: A Serious Complication Linked to GLP-1 Agonists

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, bloating, and abdominal pain. Diagnosis is typically confirmed by gastric emptying scintigraphy showing retained food after a standardized meal. The condition can lead to malnutrition, weight loss, and impaired quality of life. The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor activation. GLP-1 agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can delay nutrient delivery to the small intestine. While this effect is intended to improve postprandial glycemic control, excessive or prolonged slowing may result in clinically significant gastroparesis. The label for Ozempic lists dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) as adverse reactions with frequency below 5% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with gastroparesis, though the label does not explicitly list gastroparesis as a recognized adverse reaction.

Risk Considerations and Legal Context for New York Patients

Risk considerations center on the adequacy of warnings. The Ozempic label includes a section on hypersensitivity reactions (anaphylaxis, angioedema) but does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who develop persistent gastrointestinal symptoms may not be promptly diagnosed with gastroparesis, delaying appropriate management. The timeline between Ozempic exposure and documented harm can vary. Symptoms often emerge during dose escalation, but some patients may experience delayed onset after months of treatment. Once gastroparesis develops, it may persist even after drug discontinuation, requiring long-term dietary modifications, prokinetic agents, or other interventions. Settlement-related considerations for affected patients in New York involve evaluating whether the manufacturer provided sufficient warnings about the risk of gastroparesis. Legal claims may argue that the known pharmacological effect of delayed gastric emptying should have prompted explicit labeling about gastroparesis. Patients who have suffered severe complications—such as hospitalization, malnutrition, or permanent gastric dysfunction—may seek compensation for medical expenses, lost wages, and pain and suffering. The strength of a claim depends on establishing a clear temporal relationship between Ozempic use and the onset of gastroparesis, excluding other causes such as diabetes-related autonomic neuropathy or prior gastric surgery. In summary, Ozempic is associated with a high rate of gastrointestinal adverse reactions, and its mechanism of action can slow gastric emptying. While the label documents dyspepsia and GERD, it does not specifically warn about gastroparesis. Patients in New York who develop gastroparesis after using Ozempic should consult a medical professional for diagnosis and an attorney to assess potential legal recourse. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Ozempic and how does it work?

Ozempic (semaglutide) is a GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes. It works by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, which helps lower blood sugar levels after meals.

Can Ozempic cause gastroparesis?

While the Ozempic label does not explicitly list gastroparesis, its mechanism of slowing gastric emptying can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, and early satiety. Clinical trials show high rates of gastrointestinal adverse reactions, and some patients may develop persistent delayed gastric emptying even after stopping the drug.

What should I do if I developed gastroparesis after taking Ozempic?

If you experience persistent gastrointestinal symptoms after using Ozempic, consult a healthcare provider for proper diagnosis, which may include gastric emptying scintigraphy. If diagnosed with gastroparesis, you may want to contact a New York injury lawyer to discuss potential legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.